After a massive-scale US study, the vaccine maker on June 14 said that Novavax’s Covid-19 vaccine is over 90% effective even against coronavirus variants.
The vaccine “demonstrated 100% protection against moderate and severe disease, 90.4% overall efficacy,” the company claimed in a statement, adding, “the study included 29,960 participants across 119 sites in the United States and Mexico to examine efficacy, safety and immunogenicity.”
It also mentioned that it would be on course to produce 100 million doses and 150 million doses each month by the end of the third quarter and by the end of this year, respectively.
“Today, Novavax is one step closer to address the critical and persistent global public health requirement for additional Covid-19 vaccines,” said Stanley C. Erck, Novavax’s president and chief executive. “Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is in dire need of vaccines.”
Wherein some developed countries have made progress on inoculating their populations. But, many underdeveloped or developing countries are being left out of the global inoculation drive.
Vaccination rates across the globe’s poorest nations are far behind the Group of Seven (G7) industrialised powers and other wealthy countries regarding doses administered so far. The imbalance between the G7 and the world’s low-income countries defined by the World Bank is 73 to one.
Novavax’s vaccine, formally known as NVX-CoV2373, does not have to be preserved at ultra-low temperatures, unlike some rival vaccine makers.
The company said it was “stored at 2 degrees to 8 degree Celsius, allowing the use of existing vaccine supply chain channels for its distribution”, which means the shots should be more easily transported and administered in nations with less developed health infrastructure.